{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T10:54:15Z","timestamp":1790679255283,"version":"4.1.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Company","doi-asserted-by":"publisher","award":["IIR-ARG-001540"],"award-info":[{"award-number":["IIR-ARG-001540"]}],"id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003947","name":"Universidad Nacional de La Plata","doi-asserted-by":"publisher","award":["X679"],"award-info":[{"award-number":["X679"]}],"id":[{"id":"10.13039\/501100003947","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.ymgme.2019.10.010","type":"journal-article","created":{"date-parts":[[2019,11,3]],"date-time":"2019-11-03T01:06:38Z","timestamp":1572743198000},"page":"132-141","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":46,"title":["Pathogenesis of Fabry nephropathy: The pathways leading to fibrosis"],"prefix":"10.1016","volume":"129","author":[{"given":"Paula Adriana","family":"Rozenfeld","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"de los Angeles Bolla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Quieto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Pisani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandro","family":"Feriozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Neuman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constanza","family":"Bondar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymgme.2019.10.010_bb0005","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1056\/NEJM196705252762101","article-title":"Enzymatic defect in Fabry\u2019s disease Ceramidetrihexosidase deficiency","volume":"276","author":"Brady","year":"1967","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymgme.2019.10.010_bb0010","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1681\/ASN.2016090964","article-title":"Characterization of classical and nonclassical Fabry disease: a multicenter study","volume":"28","author":"Arends","year":"2017","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ymgme.2019.10.010_bb0015","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1007\/s00467-012-2222-9","article-title":"Renal complications of Fabry disease in children","volume":"28","author":"Najafian","year":"2013","journal-title":"Pediatr. Nephrol."},{"issue":"8","key":"10.1016\/j.ymgme.2019.10.010_bb0020","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0182379","article-title":"Retrospective study of long-term outcomes of enzyme replacement therapy in Fabry disease: analysis of prognostic factors","volume":"12","author":"Arends","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.ymgme.2019.10.010_bb0025","first-page":"31","article-title":"Long term outcomes with agalsidase alfa enzyme replacement therapy: analysis using deconstructed composite events","volume":"14","author":"Beck","year":"2018","journal-title":"Mol. Genet. Metab. Rep"},{"key":"10.1016\/j.ymgme.2019.10.010_bb0030","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1136\/jmedgenet-2014-102797","article-title":"Ten-year outcome of enzyme replacement therapy with agalsidase beta in patients with Fabry disease","volume":"52","author":"Germain","year":"2015","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.ymgme.2019.10.010_bb0035","first-page":"31","article-title":"Long-term outcomes with agalsidase alfa enzyme replacement therapy: analysis using deconstructed composite events","volume":"14","author":"Beck","year":"2017","journal-title":"Mol. Genet. Metab. Rep."},{"key":"10.1016\/j.ymgme.2019.10.010_bb0040","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/1471-2369-15-72","article-title":"Fabry nephropathy: a review - how can we optimize the management of Fabry nephropathy?","volume":"15","author":"Waldek","year":"2014","journal-title":"BMC Nephrol."},{"key":"10.1016\/j.ymgme.2019.10.010_bb0045","first-page":"6","article-title":"Efficacy of the pharmacologic chaperone migalastat in a subset of male patients with the classic phenotype of Fabry disease and migalastat-amenable variants: data from the phase 3 randomized, multicenter, double-blind clinical trial and extension study","author":"Germain","year":"2019","journal-title":"Genet Med."},{"key":"10.1016\/j.ymgme.2019.10.010_bb0050","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/ki.2010.484","article-title":"Progressive podocyte injury and globotriaosylceramide (GL-3) accumulation in young patients with Fabry disease","volume":"79","author":"Najafian","year":"2011","journal-title":"Kidney Int."},{"issue":"5","key":"10.1016\/j.ymgme.2019.10.010_bb0055","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1053\/j.ajkd.2007.12.032","article-title":"Renal biopsy findings in children and adolescents with Fabry disease and minimal albuminuria","volume":"51","author":"T\u00f8ndel","year":"2008","journal-title":"Am. J. Kidney Dis."},{"key":"10.1016\/j.ymgme.2019.10.010_bb0060","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/j.1651-2227.2003.tb00212.x","article-title":"Evolution of renal pathology in Fabry disease","volume":"92","author":"Sessa","year":"2003","journal-title":"Acta Paediatr. Suppl."},{"key":"10.1016\/j.ymgme.2019.10.010_bb0065","doi-asserted-by":"crossref","first-page":"394","DOI":"10.5414\/CNP63394","article-title":"Focal and segmental glomerular sclerosis (FSGS) in a man and a woman with Fabry\u2019s disease","volume":"63","author":"Svarstad","year":"2005","journal-title":"Clin. Nephrol."},{"key":"10.1016\/j.ymgme.2019.10.010_bb0070","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1093\/ndt\/gfp528","article-title":"Scoring system for renal pathology in Fabry disease: report of the international study group of Fabry Nephropathy (ISGFN)","volume":"25","author":"Fogo","year":"2010","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.ymgme.2019.10.010_bb0075","first-page":"C591","article-title":"Cellular mechanisms of tissue fibrosis. 3. Novel mechanisms of kidney fibrosis","volume":"304","author":"Campanholle","year":"2013","journal-title":"Am. J. Phys. Cell Phys."},{"key":"10.1016\/j.ymgme.2019.10.010_bb0080","doi-asserted-by":"crossref","first-page":"82","DOI":"10.3389\/fphys.2015.00082","article-title":"TGF-\u03b21\/Smad signaling in renal fibrosis","volume":"6","author":"Meng","year":"2015","journal-title":"Front. Physiol."},{"key":"10.1016\/j.ymgme.2019.10.010_bb0085","doi-asserted-by":"crossref","first-page":"39","DOI":"10.3109\/08923973.2015.1127382","article-title":"TGF-\u03b21: the connecting link between nephropathy and fibrosis","volume":"38","author":"Sutariya","year":"2016","journal-title":"Immunopharmacol. Immunotoxicol."},{"key":"10.1016\/j.ymgme.2019.10.010_bb0090","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.cellsig.2012.10.003","article-title":"TGF-\u03b21 signaling in tissue fibrosis: redox controls, target genes and therapeutic opportunities","volume":"25","author":"Samarakoon","year":"2013","journal-title":"Cell. Signal."},{"key":"10.1016\/j.ymgme.2019.10.010_bb0095","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.ajpath.2012.09.009","article-title":"Transforming growth factor \u03b2-1 stimulates profibrotic epithelial signaling to activate pericyte-myofibroblast transition in obstructive kidney fibrosis","volume":"182","author":"Wu","year":"2013","journal-title":"Am. J. Pathol."},{"issue":"3","key":"10.1016\/j.ymgme.2019.10.010_bb0100","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.diff.2016.05.008","article-title":"The origin of renal fibroblasts\/myofibroblasts and the signals that trigger fibrosis","volume":"92","author":"Sun","year":"2016","journal-title":"Differentiation."},{"key":"10.1016\/j.ymgme.2019.10.010_bb0105","doi-asserted-by":"crossref","first-page":"17260","DOI":"10.1073\/pnas.0605556103","article-title":"VEGF, a prosurvival factor, acts in concert with TGF-beta1 to induce endothelial cell apoptosis","volume":"103","author":"Ferrari","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ymgme.2019.10.010_bb0110","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.3892\/ijmm.2012.1139","article-title":"Possible role of transforming growth factor-\u03b21 and vascular endothelial growth factor in Fabry disease nephropathy","volume":"30","author":"Lee","year":"2012","journal-title":"Int. J. Mol. Med."},{"key":"10.1016\/j.ymgme.2019.10.010_bb0115","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1093\/ndt\/gfq306","article-title":"Globotriaosylsphingosine actions on human glomerular podocytes: implications for Fabry nephropathy","volume":"26","author":"Sanchez-Ni\u00f1o","year":"2011","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.ymgme.2019.10.010_bb0120","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0136442","article-title":"Epithelial-mesenchymal transition in kidney tubular epithelial cells induced by Globotriaosylsphingosine and Globotriaosylceramide","volume":"10","author":"Jeon","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.ymgme.2019.10.010_bb0125","doi-asserted-by":"crossref","first-page":"5049","DOI":"10.3892\/mmr.2015.4010","article-title":"Substrate-specific gene expression profiles in different kidney cell types are associated with Fabry disease","volume":"12","author":"Shin","year":"2015","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.ymgme.2019.10.010_bb0130","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s00428-011-1182-y","article-title":"Immunohistochemical diagnosis of Fabry nephropathy and localisation of globotriaosylceramide deposits in paraffin-embedded kidney tissue sections","volume":"460","author":"Valbuena","year":"2012","journal-title":"Virchows Arch."},{"key":"10.1016\/j.ymgme.2019.10.010_bb0135","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1681\/ASN.2012030316","article-title":"Agalsidase benefits renal histology in young patients with Fabry disease","volume":"24","author":"T\u00f8ndel","year":"2013","journal-title":"J. Am. Soc. Nephrol."},{"issue":"310","key":"10.1016\/j.ymgme.2019.10.010_bb0140","doi-asserted-by":"crossref","first-page":"F689","DOI":"10.1152\/ajprenal.00502.2015","article-title":"Transforming growth factor-\u03b21 and diabetic nephropathy","volume":"201","author":"Chang","year":"2016","journal-title":"Am. J. Physiol. Ren. Physiol."},{"issue":"Suppl. 1","key":"10.1016\/j.ymgme.2019.10.010_bb0145","doi-asserted-by":"crossref","first-page":"S55","DOI":"10.1097\/01.ASN.0000093460.24823.5B","article-title":"Mediators of diabetic renal disease: the case for TGF-Beta as the major mediator","volume":"15","author":"Ziyadeh","year":"2004","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ymgme.2019.10.010_bb0150","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.semnephrol.2012.06.010","article-title":"VEGF and podocytes in diabetic nephropathy","volume":"32","author":"Tufro","year":"2012","journal-title":"Semin. Nephrol."},{"key":"10.1016\/j.ymgme.2019.10.010_bb0155","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1038\/ki.2010.64","article-title":"Overexpression of VEGF-A in podocytes of adult mice causes glomerular disease","volume":"77","author":"Veron","year":"2010","journal-title":"Kidney Int."},{"key":"10.1016\/j.ymgme.2019.10.010_bb0160","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1681\/ASN.2006121304","article-title":"Interstitial vascular rarefaction and reduced VEGF-A expression in human diabetic nephropathy","volume":"18","author":"Lindenmeyer","year":"2007","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ymgme.2019.10.010_bb0165","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1159\/000369942","article-title":"VEGF-A inhibition ameliorates podocyte apoptosis via repression of activating protein 1 in diabetes","volume":"40","author":"Bai","year":"2014","journal-title":"Am. J. Nephrol."},{"key":"10.1016\/j.ymgme.2019.10.010_bb0170","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.ymgme.2011.06.007","article-title":"Higher apoptotic state in Fabry disease peripheral blood mononuclear cells: effect of globotriaosylceramide","volume":"104","author":"De Francesco","year":"2011","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2019.10.010_bb0175","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.ijcard.2017.06.079","article-title":"Evolution of cardiac pathology in classic Fabry disease: progressive cardiomyocyte enlargement leads to increased cell death and fibrosis, and correlates with severity of ventricular hypertrophy","volume":"248","author":"Frustaci","year":"2017","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.ymgme.2019.10.010_bb0180","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.matbio.2018.02.006","article-title":"Renal fibrosis: primacy of the proximal tubule","volume":"68\u201369","author":"Gewin","year":"2018","journal-title":"Matrix Biol."},{"key":"10.1016\/j.ymgme.2019.10.010_bb0185","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/ki.2013.520","article-title":"Establishing 3-nitrotyrosine as a biomarker for the vasculopathy of Fabry disease","volume":"86","author":"Shu","year":"2014","journal-title":"Kidney Int."},{"key":"10.1016\/j.ymgme.2019.10.010_bb0190","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1073\/pnas.0712309105","article-title":"Elevated globotriaosylsphingosine is a hallmark of Fabry disease","volume":"105","author":"Aerts","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ymgme.2019.10.010_bb0195","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0063506","article-title":"Dysregulated autophagy contributes to podocyte damage in Fabry\u2019s disease","volume":"8","author":"Liebau","year":"2013","journal-title":"PlosOne"},{"key":"10.1016\/j.ymgme.2019.10.010_bb0200","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1002\/cpt.790","article-title":"Lucerastat, an Iminosugar for substrate reduction therapy: tolerability, pharmacodynamics, and pharmacokinetics in patients with Fabry disease on enzyme replacement","volume":"103","author":"Gu\u00e9rard","year":"2018","journal-title":"Clin. Pharmacol. Ther."}],"container-title":["Molecular Genetics and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S109671921930318X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S109671921930318X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T12:48:18Z","timestamp":1778590098000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S109671921930318X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":40,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["S109671921930318X"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgme.2019.10.010","relation":{},"ISSN":["1096-7192"],"issn-type":[{"value":"1096-7192","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pathogenesis of Fabry nephropathy: The pathways leading to fibrosis","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgme.2019.10.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}